About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Strides Arcolab Inks Deal With Gilead Sciences for HIV Drug

by Vishnuprasad on January 22, 2015 at 7:20 PM
Font : A-A+

 Strides Arcolab Inks Deal With Gilead Sciences for HIV Drug

Indian pharmaceutical company Strides Arcolab has entered into a licensing agreement with US-based Gilead Sciences to manufacture and distribute latter's low-cost HIV drug, Tenofovir Alafenamide (TAF), in developing countries.

In a BSE filing, Strides Arcolab said, "It has entered into a licensing agreement with Gilead Sciences, Inc under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs."

Advertisement

Strides said that the license being granted to it extends to 112 countries.

"Strides will receive technology transfer from Gilead, enabling Strides to manufacture low cost versions of TAF for developing countries," the company stated.

TAF is an investigational product in the US and have not yet been determined safe and efficacious in humans.



Source: Medindia
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest AIDS/HIV News

 HIV Antibody Response Raised in Patients With Tuberculosis Disease
A new study has found that the co-localization of tuberculosis disease and HIV in lymphatic tissues leads to the emergence of potent HIV antibodies.
Exploring the Consistent Outcomes of an Antiviral Drug
Specific antiviral drug that is widely used to treat smallpox patients since last summer's outbreak is found to produce similar outcomes regardless of the patient's HIV status.
Why Is STI and HIV Screening Decreased While Positive Test Results Increase?
In susceptible communities because of poverty, and racism, the effects of inadequate STI and HIV screening may be more profound.
Who Is Responsible for the Blunting of AIDS Epidemic?
In India, annual HIV infections and AIDS-related deaths continue to drop. Between 2010 and 2021, new HIV infections dropped by 46%.
Are Countries Missing on HIV Self-Testing?
Globally, all countries have promised to end AIDS by 2030, for which it is essential to safeguard individuals living with HIV to complete HIV care services.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Strides Arcolab Inks Deal With Gilead Sciences for HIV Drug Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests